Abstract: Objective To evaluate the pharmacological effects of Reyanning Heji on mouse animal of respiratory infections caused by the influenza virus, Streptococcus pneumoniae and hemolytic streptococcus. Methods Reyanning Heji (5, 10, 20 mL·kg^-1 for mice, 2.5,5,10 mL·kg^-1 for rats, which were half, equivalent to and double the clinical dose for humans) was used to treat the mouse models of pneumonia caused by influenza virus H1N1 / FM1, Streptococcus pneumoniae and hemolytic streptococcus. The lung index, death rate, death protection rate, life extension rate and pharyngeal pathology of the rats in each group were recorded. Results Reyanning Heji could significantly reduce the lung index of mice with viral pneumonia caused by influenza virus H1N1 / FM1. The inhibition rate of the lung index by Reyanning Heji in the medium dose group was 61.98%. Reyanning Heji could reduce the mortality of mice. The high and medium doses of Reyanning Heji could significantly reduce the lung index of mice with bacterial pneumonia caused by Streptococcus pneumoniae. Reyanning Heji could reduce the mortality of mice with bacterial respiratory infections caused by hemolytic streptococcus. The survival of mice in the medium and low dose groups was prolonged. In the low dose group, the pharyngeal lesions of rats were significantly improved while the pharyngeal lesion score was reduced. Conclusion Reyanning Heji has significant therapeutic effects against the mouse models of respiratory infections caused by the influenza virus, streptococcus pneumoniae, and hemolytic streptococcus. The therapeutic effect is equivalent to that of oseltamivir and amoxicillin at the clinical dosage.

Key words: infectious animal model, anti-infection, Reyanning Heji, respiratory system, pharmacological effects, pneumonia, influenza virus, streptococcus pneumonia, hemolytic streptococcus